Renal cancer: Molecular mechanisms and newer therapeutic options

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 1, 2002, Pages 37-42

  Karumanchi, S Ananth ^a   Merchan, Jaime ^a   Sukhatme, Vikas P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; INTERLEUKIN 2;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; GENE MUTATION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; ONCOCYTOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE;

ADENOMA, OXYPHILIC; ANIMALS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR BIOLOGY;

EID: 0036140913     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200201000-00006     Document Type: Review

References (53)

1. Epidemiologic aspects of renal cell cancer
2. Contemporary approach to the classification of renal epithelial tumors
3. Advances in the molecular basis of renal neoplasia
4. Genetic and clinical aspects of familial renal neoplasms
5. Mutations of the VHL tumour suppressor gene in renal carcinoma
6. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients
7. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice
8. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor
9. Transforming growth factor beta 1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma
10. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene
11. VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells
12. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor
13. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
14. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
15. Role of transforming growth factor-alpha in von Hippel-Lindau [VHL][-/-] clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
16. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
17. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex
18. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
19. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
20. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
21. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing
22. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1 alpha in clear cell renal carcinomas
23. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer
24. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion
25. Von Hippel-Lindau gene mutations in N-nitrosodimethylamine-induced rat renal epithelial tumors
26. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma
27. Tuberous sclerosis-associated renal cell carcinoma: Clinical, pathological, and genetic features
28. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors
29. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
30. Novel mutations of the MET proto-oncogene in papillary renal carcinomas
31. Activating mutations for the met tyrosine kinase receptor in human cancer
32. Should radical nephrectomy be performed in the face of surgically incurable disease?
33. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer
34. The palliation of symptomatic osseous metastases: Final results of the study by the Radiation Therapy Oncology Group
35. Interferon in metastatic renal cell carcinoma
36. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study
37. Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997
38. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma
39. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
40. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
41. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
42. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
43. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response
44. Clinical applications of angiogenic growth factors and their inhibitors
45. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
46. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
47. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma
48. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
49. Cyclosporine induces cancer progression by a cell-autonomous mechanism
50. Endostatin: Yeast production, mutants, and antitumor effect in renal cell carcinoma
51. Altered expression of transforming growth factor-alpha: An early event in renal cell carcinoma development
52. Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas
53. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies